Bayesian Methods in Regulatory Science

References

• Anscombe, F. J. (1963), “Sequential Medical Trials,” Journal of the American Statistical Association, 58, 365–383. DOI: 10.1080/01621459.1963.10500851.
   Web of Science ®Google Scholar
• Armitage, P. (1960), Sequential Medical Trials, Springfield, IL: Thomas.
   Google Scholar
• Barnard, G. A. (1946), “Sequential Tests in Industrial Statistics,” Journal of the Royal Statistical Society, Series B, 8, 1–26. DOI: 10.2307/2983610.
   Google Scholar
• Berger, J. O., and Berry, D. A. (1988), “Statistical Analysis and the Illusion of Objectivity,” American Scientist, 76, 159–165.
   Web of Science ®Google Scholar
• Bernardo, J. M. (1997), “Statistical Inference as a Decision Problem: The Choice of Sample Size,” Statistician, 46, 151–153. DOI: 10.1111/1467-9884.00071.
   Google Scholar
• Berry, S. M., Carlin, B. P., Lee, J. J., and Müller, P. (2011), Bayesian Adaptive Methods for Clinical Trials, Boca Raton, FL: CRC Press.
   Google Scholar
• Brockwell, A. E., and Kadane, J. B. (2003), “A Gridding Method for Bayesian Sequential Decision Problems,” Journal of Computational and Graphical Statistics, 12, 566–584. DOI: 10.1198/1061860032274.
   Web of Science ®Google Scholar
• Campbell, G. (2011), “Bayesian Statistics in Medical Devices: Innovation Sparked by the FDA,” Journal of Biopharmaceutical Statistics, 21, 871–887. DOI: 10.1080/10543406.2011.589638.
   PubMed Web of Science ®Google Scholar
• Carlin, B. P., Kadane, J. B., and Gelfand, A. E. (1998), “Approaches for Optimal Sequential Decision Analysis in Clinical Trials,” Biometrics, 54, 964–975. DOI: 10.2307/2533849.
   PubMed Web of Science ®Google Scholar
• Cheng, Y., Su, F., and Berry, D. A. (2003), “Choosing Sample Size for a Clinical Trial Using Decision Analysis,” Biometrika, 90, 923–936. DOI: 10.1093/biomet/90.4.923.
   Web of Science ®Google Scholar
• Colton, T. (1963), “A Model for Selecting One of Two Medical Treatments,” Journal of the American Statistical Association, 58, 388–400. DOI: 10.1080/01621459.1963.10500853.
   Web of Science ®Google Scholar
• Davidian, M., and Giltinan, D. (1995), Nonlinear Models for Repeated Measurement Data, London: Chapman & Hall.
   Google Scholar
• De Santis, F., and Gubbiotti, S. (2017), “A Decision-Theoretic Approach to Sample Size Determination Under Several Priors,” Applied Stochastic Models in Business and Industry, 33, 282–295. DOI: 10.1002/asmb.2211.
   Web of Science ®Google Scholar
• Devlin, N. J., and Lorgelly, P. K. (2017), “QALYs as a Measure of Value in Cancer,” Journal of Cancer Policy, 11, 19–25. DOI: 10.1016/j.jcpo.2016.09.005.
   Web of Science ®Google Scholar
• Ding, M., Rosner, G. L., and Mueller, P. (2008), “Bayesian Optimal Design for Phase II Screening Trials,” Biometrics, 64, 886–894. DOI: 10.1111/j.1541-0420.2007.00951.x.
   PubMed Web of Science ®Google Scholar
• Ezzalfani, M., Zohar, S., Qin, R., Mandrekar, S. J., and Deley, M.-C. L. (2013), “Dose-Finding Designs Using a Novel Quasi-Continuous Endpoint for Multiple Toxicities,” Statistics in Medicine, 32, 2728–2746. DOI: 10.1002/sim.5737.
   PubMedGoogle Scholar
• FDA (2018), “Advancing Regulatory Science,” available at https://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/default.htm.
   Google Scholar
• Fisher, R. A. (1954), Statistical Methods for Research Workers (12th ed., rev. ed.), Edinburgh: Oliver and Boyd.
   Google Scholar
• Gamalo-Siebers, M., Savic, J., Basu, C., Zhao, X., Gopalakrishnan, M., Gao, A., Song, G., Baygani, S., Thompson, L., Xia, H. A., Price, K., Tiwari, R., and Carlin, B. P. (2017), “Statistical Modeling for Bayesian Extrapolation of Adult Clinical Trial Information in Pediatric Drug Evaluation,” Pharmaceutical Statistics, 16, 232–249. DOI: 10.1002/pst.1807.
   PubMed Web of Science ®Google Scholar
• Goodman, S. N. (1999a), “Toward Evidence-Based Medical Statistics. 1: The p Value Fallacy,” Annals of Internal Medicine, 130, 995–1004. DOI: 10.7326/0003-4819-130-12-199906150-00008.
   PubMed Web of Science ®Google Scholar
• Goodman, S. N. (1999b), “Toward Evidence-Based Medical Statistics. 2: The Bayes Factor,” Annals of Internal Medicine, 130, 1005–1013. DOI: 10.7326/0003-4819-130-12-199906150-00019.
   PubMed Web of Science ®Google Scholar
• Harrington, D., D’Agostino, R. B., Gatsonis, C., Hogan, J. W., Hunter, D. J., Normand, S.-L. T., Drazen, J. M., and Hamel, M. B. (2019), “New Guidelines for Statistical Reporting in the Journal,” New England Journal of Medicine, 381, 285–286. DOI: 10.1056/NEJMe1906559.
   PubMed Web of Science ®Google Scholar
• Henriquez, R. R., and Korpi-Steiner, N. (2016), “Bayesian Inference Dilemma in Medical Decision-Making: A Need for User-Friendly Probabilistic Reasoning Tools,” The Clinical Chemist, 62, 1285–1286. DOI: 10.1373/clinchem.2016.260935.
   Web of Science ®Google Scholar
• Johnson, V. E. (2005), “Bayes Factors Based on Test Statistics,” Journal of the Royal Statistical Society, Series B, 67, 689–701. DOI: 10.1111/j.1467-9868.2005.00521.x.
   Google Scholar
• Johnson, V. E., and Cook, J. D. (2009), “Bayesian Design of Single-Arm Phase II Clinical Trials With Continuous Monitoring,” Clinical Trials, 6, 217–226. DOI: 10.1177/1740774509105221.
   PubMed Web of Science ®Google Scholar
• Kass, R. E., and Raftery, A. E. (1995), “Bayes Factors,” Journal of the American Statistical Association, 90, 773–795. DOI: 10.1080/01621459.1995.10476572.
   Web of Science ®Google Scholar
• Lewis, R. J., Lipsky, A. M., and Berry, D. A. (2007), “Bayesian Decision-Theoretic Group Sequential Clinical Trial Design Based on a Quadratic Loss Function: A Frequentist Evaluation,” Clinical Trials, 4, 5–14. DOI: 10.1177/1740774506075764.
   PubMed Web of Science ®Google Scholar
• Lindley, D. V. (1985), Making Decisions (2nd ed.), London: Wiley.
   Google Scholar
• Lindley, D. V. (1998), “Decision Analysis and Bioequivalence Trials,” Statistical Science, 13, 136–141. DOI: 10.1214/ss/1028905932.
   Web of Science ®Google Scholar
• Little, R. J. (2006), “Calibrated Bayes: A Bayes/Frequentist Roadmap,” The American Statistician, 60, 213–223. DOI: 10.1198/000313006X117837.
   Web of Science ®Google Scholar
• Manski, C. F. (2019), “Treatment Choice With Trial Data: Statistical Decision Theory Should Supplant Hypothesis Testing,” The American Statistician, 73, 296–304. DOI: 10.1080/00031305.2018.1513377.
   PubMed Web of Science ®Google Scholar
• Meregaglia, M., and Cairns, J. (2017), “A Systematic Literature Review of Health State Utility Values in Head and Neck Cancer,” Health and Quality of Life Outcomes, 15, 174. DOI: 10.1186/s12955-017-0748-z.
   PubMed Web of Science ®Google Scholar
• Müller, P., Berry, D. A., Grieve, A. P., Smith, M., and Krams, M. (2007), “Simulation-Based Sequential Bayesian Design,” Journal of Statistical Planning and Inference, 137, 3140–3150. DOI: 10.1016/j.jspi.2006.05.021.
   Web of Science ®Google Scholar
• Müller, P., Xu, Y., and Thall, P. F. (2017), “Clinical Trial Design as a Decision Problem,” Applied Stochastic Models in Business and Industry, 33, 296–301. DOI: 10.1002/asmb.2222.
   PubMed Web of Science ®Google Scholar
• Neyman, J., and Pearson, E. S. (1928a), “On the Use and Interpretation of Certain Test Criteria for Purposes of Statistical Inference. Part I,” Biometrika, 20A, 175–240. DOI: 10.2307/2331945.
   Google Scholar
• Neyman, J., and Pearson, E. S. (1928b), “On the Use and Interpretation of Certain Test Criteria for Purposes of Statistical Inference. Part II,” Biometrika, 20A, 263–294. DOI: 10.2307/2332112.
   Google Scholar
• Neyman, J., and Pearson, E. S. (1933), “On the Problem of the Most Efficient Tests of Statistical Hypotheses,” Philosophical Transactions of the Royal Society of London, Series A, 231, 289–337. DOI: 10.1098/rsta.1933.0009.
   Google Scholar
• Operskalski, J. T., and Barbey, A. K. (2016), “Risk Literacy in Medical Decision-Making,” Science, 352, 413–414. DOI: 10.1126/science.aaf7966.
   PubMed Web of Science ®Google Scholar
• Raiffa, H., and Schlaifer, R. (2000), Applied Statistical Decision Theory, Wiley Classics Library, New York: Wiley.
   Google Scholar
• Ramaekers, B. L., Joore, M. A., Grutters, J. P., van den Ende, P., de Jong, J., Houben, R., Lambin, P., Christianen, M., Beetz, I., Pijls-Johannesma, M., and Langendijk, J. A. (2011), “The Impact of Late Treatment-Toxicity on Generic Health-Related Quality of Life in Head and Neck Cancer Patients After Radiotherapy,” Oral Oncology, 47, 768–774. DOI: 10.1016/j.oraloncology.2011.05.012.
   PubMed Web of Science ®Google Scholar
• Rossell, D., Mueller, P., and Rosner, G. L. (2007), “Screening Designs for Drug Development,” Biostatistics, 8, 595–608. DOI: 10.1093/biostatistics/kxl031.
   PubMed Web of Science ®Google Scholar
• Schoenfeld, D. A., Hui, Z., and Finkelstein, D. M. (2009), “Bayesian Design Using Adult Data to Augment Pediatric Trials,” Clinical Trials, 6, 297–304.
   PubMed Web of Science ®Google Scholar
• Sebastiani, P., and Wynn, H. P. (2000), “Maximum Entropy Sampling and Optimal Bayesian Experimental Design,” Journal of the Royal Statistical Society, Series B, 62, 145–157. DOI: 10.1111/1467-9868.00225.
   Google Scholar
• Sheiner, L. B. (1997), “Learning Versus Confirming in Clinical Drug Development,” Clinical Pharmacology and Therapeutics, 61, 275–291. DOI: 10.1016/S0009-9236(97)90160-0.
   PubMed Web of Science ®Google Scholar
• Spiegelhalter, D. J., Abrams, R. K., and Myles, J. P. (2004), Bayesian Approaches to Clinical Trials and Health-Care Evaluation, Chichester, UK: Wiley.
   Google Scholar
• Stallard, N., Miller, F., Day, S., Hee, S. W., Madan, J., Zohar, S., and Posch, M. (2017), “Determination of the Optimal Sample Size for a Clinical Trial Accounting for the Population Size,” Biometrical Journal, 59, 609–625. DOI: 10.1002/bimj.201500228.
   PubMed Web of Science ®Google Scholar
• Stallard, N., Thall, P., and Whitehead, J. (1999), “Decision Theoretic Designs for Phase II Clinical Trials With Multiple Outcomes,” Biometrics, 55, 971–977. DOI: 10.1111/j.0006-341X.1999.00971.x.
   PubMed Web of Science ®Google Scholar
• Stroud, J. R., Müller, P., and Rosner, G. L. (2001), “Optimal Sampling Times in Population Pharmacokinetic Studies,” Journal of the Royal Statistical Society, Series C, 50, 345–359. DOI: 10.1111/1467-9876.00239.
   Web of Science ®Google Scholar
• Thall, P. F. and Cook, J. D. (2004), “Dose-Finding Based on Efficacy-Toxicity Trade-Offs,” Biometrics, 60, 684–693. DOI: 10.1111/j.0006-341X.2004.00218.x.
   PubMed Web of Science ®Google Scholar
• Ventz, S., Cellamare, M., Bacallado, S., and Trippa, L. (2019), “Bayesian Uncertainty Directed Trial Designs,” Journal of the American Statistical Association, 114, 962–974. DOI: 10.1080/01621459.2018.1497497.
   Web of Science ®Google Scholar
• Wald, A. (1945), “Sequential Tests of Statistical Hypotheses,” Annals of Mathematical Statistics, 16, 117–186. DOI: 10.1214/aoms/1177731118.
   Google Scholar
• Wasserstein, R. L., and Lazar, N. A. (2016), “The ASA Statement on p-Values: Context, Process, and Purpose,” The American Statistician, 70, 129–133. DOI: 10.1080/00031305.2016.1154108.
   Web of Science ®Google Scholar
• Weinstein, M. C., Torrance, G., and McGuire, A. (2009), “QALYs: THE BASICS,” Value in Health, 12, S5–S9. DOI: 10.1111/j.1524-4733.2009.00515.x.
   PubMed Web of Science ®Google Scholar
• Yuan, Y., Nguyen, H. Q., and Thall, P. F. (2016), Bayesian Designs for Phase I-II Clinical Trials, Boca Raton, FL: Chapman & Hall.
   Google Scholar